DNLI - Baird sees 244% upside in Eiger Bio in premarket analyst action January, 29 2019 09:03 AM Denali Therapeutics Inc. Eiger BioPharmaceuticals (NASDAQ:EIGR) initiated with Outperform rating and $47 (244% upside) price target at Baird. Shares up 13% premarket. More news on: Eiger BioPharmaceuticals, Inc., Vericel Corporation, Denali Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...